The patient was a 64-year-old female, she was initially diagnosed with PMF, and then she developed B-ALL 17 months later after receiving treatment of prednisone, danazole, levamisole, aspirin, thalidomide and jaktinib. After induction therapy, the patient received 8 months of continuous remission, and then the reexamination showed relapse. There was no remission after reinduction therapy. The patient gave up treatment and was discharged 2 months later. JAK2 V617F genemutation was positive before and after leukemia transformation.
Conclusions:
The patients with transformation of PMF to B-ALL have poor clinical prognosis and short survivaltime. The possible mechanism of its transformation may be related to additional genetic events or certain high-riskgenes. However, the specific mechanism is still unclear, and further investigation of the etiology is needed to seek targeted treatment.